The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease

Completed · Not applicable

Conditions studied: Lymphatic Disease, HIV Infections

In brief

The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of Isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of the 28 days of treatment), measured by one or more of the following immunological parameters: * Increase in natural killer (NK) cell activity. * Increase in total T-cells (OKT-11). * Increases in absolute number and percentage of T-helper cells (OKT-4).

Key facts

Study ID

NCT00002296

Run by

Newport Pharmaceuticals International

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: not accepted.

You may not qualify if…

• Co-existing Condition:
• Patients with the following are excluded:
• History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction and severe gastric ulcer.
• Lymphoid malignancy.
• Infectious mononucleosis caused by cytomegalovirus or Epstein-Barr virus.
• Heart disease (especially if receiving cardiac glycosides).
• Hemophilia.
• Patients with the following are excluded:
• Kaposi's sarcoma or overt opportunistic infections as follows:
• Candida albicans, Pneumocystis carinii, Herpes simplex, Cryptococcus neoformans, Histoplasma capsulatum, Mycobacterium avium-intracellulare, Toxoplasma gondii, Legionella, Cryptosporidium, Isospora, and Papovavirus.
• Active evidence of infectious mononucleosis caused by Epstein-Barr virus (EBV) or cytomegalovirus (CMV) as determined by heterophil test (EBV) or cell culture (CMV).
• History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, and severe gastric ulcer.
• Critical illness.
• Condition requiring hospitalization.
• Women of childbearing age are excluded.
• Hemophilia.
• Prior Medication:
• Excluded:
• Steroids.
• Cytotoxic immunosuppressive agents.
• Antiviral medicine.
• Prior Treatment:
• Excluded:
• Radiotherapy.
• Patients who have unexplained immunodepression and are at risk of developing AIDS.

Where it is running

• Newport Pharmaceuticals International Inc — Laguna Hills, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.